我国药品制造企业纵向一体化对企业绩效的影响研究

发布时间：2018-06-04 02:31

本文选题：纵向一体化 + 药品制造企业　；参考：《上海师范大学》2013年硕士论文

【摘要】：自改革开放以来，我国药品制造业得到了迅速发展，许多大型药品制造企业面临规模扩张，需要选择未来的发展模式及战略。在这种背景下，一些大型企业着手于收购重组上游企业或自建原料药制造企业，实施纵向一体化战略，试图解决契约不完备、信息不对称等问题，达到技术人才资源共享。但是，纵向一体化一方面可以提高企业的垄断势力，降低交易成本，另一方面却会因为规模变大而增加管理成本。对于药品制造企业而言，纵向一体化是否能提高企业的绩效？政府是否应该鼓励药品制造业向其他产业链延伸？所以，研究纵向一体化问题能为政府制定药品制造业整合政策提供理论支持，为药品制造业规模扩张及未来的发展模式选择提供建议。本文首先系统综述了国内外纵向一体化的理论和研究成果，之后分析了我国药品制造业纵向一体化的现状，揭示出我国药品制造业呈现一体化规模扩大、整合原料药企业及外包业务回归一体化经营的趋势。而对纵向一体化对于药品制造企业绩效的影响分析看，纵向一体化能为药品制造企业稳定上游产品的供给，能提高药品制造企业的市场垄断力，同时能降低药品制造企业的交易成本。在实证研究方面，本文运用药品制造企业2001年-2010年的数据测量了其纵向一体化程度，并将我国药品制造企业的纵向一体化指数与其绩效进行检验，得出了两者呈现正相关关系的结论。国内外尚未有对药品制造企业的纵向一体化程度与其绩效之间的关系做过系统性的研究。本文将运用经济学相关理论与已有模型，结合我国药品制造企业的纵向一体化发展情况，，采用I/O模型中的Davies-Morris指数法测量药品制造企业的一体化程度，并运用SPSS软件对影响其绩效的几个因素进行回归分析。本文通过分析得出了我国药品制造企业通过纵向一体化能够将外部性问题转为内部性问题，提高其市场集中度，降低药品制造企业的市场交易成本，避免契约不完备、策略选择风险以及套牢等带来的风险，给药品制造业带来规模正效益。随着药品制造企业纵向一体化程度的增加，药品制造企业的绩效也在提高，两者呈现正相关关系。政府应该鼓励有能力的药品制造企业实施纵向一体化战略，鼓励药品制造业向上下游产业链延伸，促进药品制造企业生产整合。
[Abstract]:Since the reform and opening up, the pharmaceutical manufacturing industry in China has been developing rapidly. Many large pharmaceutical manufacturing enterprises are facing the expansion of scale and need to choose the future development model and strategy. Under this background, some large enterprises begin to acquire and reorganize upstream enterprises or build their own raw drug manufacturing enterprises, implement vertical integration strategy, try to solve the problems of incomplete contracts and asymmetric information, so as to achieve the sharing of technical talent resources. However, on the one hand, vertical integration can increase monopoly power and reduce transaction cost, on the other hand, it will increase management cost because of increasing scale. For pharmaceutical manufacturing enterprises, can vertical integration improve their performance? Should the government encourage the pharmaceutical industry to expand into other industrial chains? Therefore, the study of vertical integration can provide theoretical support for the government to formulate the integrated policy of pharmaceutical manufacturing industry, and provide suggestions for the scale expansion of pharmaceutical manufacturing industry and the choice of future development model. This paper firstly summarizes the theory and research results of vertical integration at home and abroad, then analyzes the present situation of vertical integration of pharmaceutical manufacturing industry in China, and reveals that the scale of integration of pharmaceutical manufacturing industry in China is expanding. Integration of API enterprises and outsourcing business return to the trend of integrated management. From the analysis of the effect of vertical integration on the performance of pharmaceutical manufacturing enterprises, it can be seen that vertical integration can stabilize the supply of upstream products and enhance the market monopoly power of pharmaceutical manufacturing enterprises. At the same time, it can reduce the transaction cost of pharmaceutical manufacturers. In the aspect of empirical research, this paper uses the data of pharmaceutical manufacturing enterprises from 2001 to 2010 to measure the degree of vertical integration, and tests the vertical integration index and its performance of Chinese pharmaceutical manufacturing enterprises. The conclusion of positive correlation between the two is obtained. No systematic research has been done on the relationship between the degree of vertical integration and the performance of pharmaceutical manufacturing enterprises at home and abroad. In this paper, we will use the relevant theories of economics and existing models, combining with the development of vertical integration of pharmaceutical manufacturing enterprises in China, using the Davies-Morris index method in the I / O model to measure the degree of integration of pharmaceutical manufacturing enterprises. And use SPSS software to influence its performance several factors to carry on the regression analysis. Through the analysis, this paper concludes that the drug manufacturing enterprises in our country can turn the externality into internal problems through vertical integration, improve their market concentration, reduce the market transaction cost of the pharmaceutical manufacturing enterprises, and avoid the incomplete contract. The strategic choice risk and the risk brought about by clamping up will bring the scale positive benefit to the pharmaceutical manufacturing industry. With the increase of the degree of vertical integration of pharmaceutical manufacturing enterprises, the performance of pharmaceutical manufacturing enterprises is also improving, which shows a positive correlation. The government should encourage the competent pharmaceutical manufacturing enterprises to implement vertical integration strategy, encourage the pharmaceutical manufacturing industry to extend to the upstream and downstream industrial chains, and promote the production integration of pharmaceutical manufacturing enterprises.
【学位授予单位】：上海师范大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：F272.5;F426.72

【参考文献】